Thesis
I just bought shares in Reviva Pharma because they've resolved their cash issues with an infusion of $18 million, and I believe their new product, Brilaroxazine, is set to disrupt the schizophrenia market. The potential upside is massive, and I'm confident that once they submit their NDA in early 2026, the stock price will start to climb.